Dose-dependent Changes of the Ratio of Apoptosis to Proliferation by Norethisterone and Medroxyprogesterone Acetate in Human Breast Epithelial Cells

Abstract

Objective: There is increasing evidence that adding progestogens to estrogen replacement therapy may do more harm than good; however, whether all progestogens act equally on breast cells is debatable. Apart from estrogens, mitogenic growth factors from stromal breast tissue are important in growth-regulation of breast cells, and may modify the response to progestogens. We investigated the effects of medroxyprogesterone acetate (MPA) as well as norethisterone (NET) in the presence of a growth factor mixture and/or estradiol in normal and cancerous human epithelial breast cells. Methods: MCF10A cells (human epithelial, estrogen- and progesterone-receptor negative, normal breast cells), HCC1500 (human estrogen and progesterone receptor-positive primary breast cancer cells) and MCF-7 cells (human estrogen and progesterone receptor-positive metastatic breast cancer cell line) were used in the experiments. The cells were incubated with progestogens at concentrations of 10 ^{- 10} to 10 ^{- 6} M for 7 days and growth factors (GFs), estradiol (E2) alone and a combination of GFs + E2. Cell proliferation rate was measured by ATP assay. Apoptosis was measured by cell death assay. Ratios of cell death : proliferation were calculated from these results. Results: In MCF10A cells growth factors elicited a decrease in the ratio of apoptosis to proliferation. This effect was further stimulated by the addition of MPA, whereas NET had no effect. In HCC cells growth factors and estradiol alone and in combination led to a reduction in the ratio. This effect could be partly reversed dose-dependently by the addition of MPA and NET, being more pronounced for MPA. Similar results were found for MCF-7 cells stimulated by estradiol. Conclusion: The results of our investigations demonstrate that there are differences between the two progestogens NET and MPA investigated with respect to their effects on normal and cancerous cells. By increasing the mitotic rate of normal epithelial cells, MPA may increase breast cancer risk in women when used in long-term treatment. In this respect NET reacts neutral. The mitosis of pre-existing cancerous cells may be partly inhibited by the addition of both progestogens. Thus, our results indicate that it is necessary to differentiate between normal and malignant breast cells concerning the assessment of progestogens as a risk factor for breast carcinogenesis.

Key words

Norethisterone - Medroxyprogesterone acetate - Normal and cancerous breast cells - Apoptosis to proliferation ratio

References

• 1 Beatson G T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases.  Lancet. 1896;  2 104-107
• 2 Clemons M, Goss P. Estrogen and the risk of breast cancer.  New Engl J Med. 2001;  344 276-285
• 3 Writing Group for the Women’s Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women.  JAMA. 2002;  288 321-333
• 4 Million Women Study Collaborators . Breast Cancer and hormone replacement therapy in the Million Women Study.  Lancet. 2003;  362 419-427
• 5 The Women’s Health Initiative Steering Committee . Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy. The Women’s Health Initiative Randomised Controlled Trial.  JAMA. 2004;  291 1701-1712
• 6 Dickson R B, Lippman M E. Growth factors in breast cancer.  Endocrine Reviews. 1995;  16 559-589
• 7 Rahmean K MW, Sarkar F H. Steroid hormone mimics: molecular mechanisms of cell growth and apoptosis in normal and malignant mammary epithelial cells.  J Steroid Biochem Mol Biol. 2002;  80 191-201
• 8 Andreotti P E, Thornthwaite J T, Morse I S. ATP Tumor Chemosensitivity Assay. In: Stanley P, Kricka LJ (eds) Bioluminescence and Chemoluminescence: Current Status. Chichester; J. Wiley & Sons 1991: 417-420
• 9 Cell Death Detection ELISA, Cat. No. 1 544 675, Version 4. Roche Applied Science 2003
• 10 Bergkvist L, Adami H O, Persson I, Hoover R, Shairer C. The risk of breast cancer after oestrogen-progestin replacement.  N Engl J Med. 1989;  321 293-297
• 11 Persson I, Yuen J, Bergkvist L, Adami H O, Hoover R, Schairer C. Combined oestrogen-progestogen replacement therapy and breast cancer risk.  Lancet. 1992;  340 1004
• 12 Magnusson C, Baron J A, Bergström R, Adami H O, Persson I. Breast cancer risk following long-term oestrogen- and oestrogen-progestin replacement therapy.  Int J Cancer. 1999;  81 339-344
• 13 Collaborative Group on Hormonal Factors in Breast Cancer . Breast Cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer.  Lancet. 1997;  350 1047-1059
• 14 Russo J, Ao X, Grill C, Russo I H. Pattern of distribution of cells positive for estrogen receptor-a and progesterone receptor in relation to proliferating cells in the mammary gland.  Breast Cancer Res. 1999;  53 217-227
• 15 Catherino W H, Jeng M H, Jordan V C. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.  Brit J Cancer. 1993;  67 945-952
• 16 Schoonen W GEJ, Joosten J WH, Kloosterboer H J. Effects of two classes of progestogens, Pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells:1.MCF-7 cell lines.  J Steroid Biochem Mol Biol. 1995;  55 423-437
• 17 Hofseth L J, Raafat A M, Osuch J R, Pathak D R, Slomski C A, Haslam S Z. Hormone Replacement Therapy with Estrogen or Estrogen plus Medroxyprogesterone Acetate Is Associated with Increased Epithelial Proliferation in the Normal Postmenopausal Breast.  J Clin Endocrinol Metab. 1999;  84 4559-4565
• 18 Cline J M, Soderqvist G S, von Schoultz E, Skoog L, von Schoulz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques.  Am J Obstet Gynecol. 1996;  174 93-100
• 19 Cappelletti V, Miodini P, Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines.  Anticancer Res. 1995;  15 2551-2556
• 20 Seeger H, Wallwiener D, Mueck A O. The Effect of Progesterone and Synthetic Progestins on Serum- and Estradiol-Stimulated Proliferation of Human Breast Cancer Cells.  Hormone Metab Res. 2003;  35 76-80
• 21 Franke H R, Vermes I. Differential effects of progestogens on breast cancer cell lines.  Maturitas. 2003;  46S1 S55-S58
• 22 Preston-Martin S, Pike M C, Ross R K, Jones P A, Henderson B E. Increased cell division as a cause of human cancer.  Cancer Res. 1990;  50 7415-7421
• 23 Svensson L O, Johnson S H, Olsson S E. Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil®, Trisequence®/Provera®, and Divina®. A randomised, single-blind, triple cross-over bioavailability study in menopausal women.  Maturitas. 1994;  18 229-238
• 24 Stanczyk F Z, Brenner P F, Mishell D R, Ortiz A, Gentzschein E KE, Goebelsmann U. A radioimmunoassay for norethindrone (NET): measurement of serum net concentrations following ingestion of NET-containing oral contraceptive steroids.  Contraception. 1978;  18 615-633